New and emerging HDAC inhibitors for cancer treatment

ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform

Rhodes, D. R., Yu, J., Sundaram, S. K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T. R., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,615 · see citing works

Anticancer activities of histone deacetylase inhibitors

Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · see citing works

HDAC6 is a microtubule-associated deacetylase

Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · see citing works

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

Fraga, M. F., Ballestar, E., Villar‐Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C. E., Ropero, S., Petrie, K. R., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,926 · see citing works

Identification of 67 Histone Marks and Histone Lysine Crotonylation as a New Type of Histone Modification

Tan, M., Luo, H., Lee, S., Jin, F., Yang, J. S., Montellier, E., Buchou, T., Cheng, Z., Rousseaux, S., Rajagopal, N., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.008 · Cited by 1,902 · see citing works

Acetylation and deacetylation of non-histone proteins

Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584 · see citing works

The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress

Kawaguchi, Y., Kovacs, J. J., McLaurin, A. C., Vance, J. M., Ito, A., & Yao, T. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,529 · see citing works

HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor

Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153 · see citing works

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141 · see citing works

Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation

Zhang, Y., Ng, H.-H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999) · Genes & Development · doi:10.1101/gad.13.15.1924 · Cited by 1,103 · see citing works

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066 · see citing works

Role of the histone deacetylase complex in acute promyelocytic leukaemia

Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., & Evans, R. M. (1998) · Nature · doi:10.1038/35895 · Cited by 1,060 · see citing works

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S. R. S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,057 · see citing works

Histone deacetylases and cancer

Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031 · see citing works

Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia

Grignani, F., Matteis, S. D., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., et al. (1998) · Nature · doi:10.1038/35901 · Cited by 1,004 · see citing works

Deacetylase inhibition promotes the generation and function of regulatory T cells

Tao, R. N., de Zoeten, E. F., Özkaynak, E., Chen, C., Wang, L., Porrett, P. M., Li, B., Turka, L. A., Olson, E. N., Greene, M. I., et al. (2007) · Nature Medicine · doi:10.1038/nm1652 · Cited by 930 · see citing works

Deacetylation of p53 modulates its effect on cell growth and apoptosis

Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. J. (2000) · Nature · doi:10.1038/35042612 · Cited by 818 · see citing works

n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells

Riggs, M. G., WHITTAKER, R. G., Neumann, J. R., & Ingram, V. M. (1977) · Nature · doi:10.1038/268462a0 · Cited by 777 · see citing works

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500186200 · Cited by 755 · see citing works

Enzymatic Activity Associated with Class II HDACs Is Dependent on a Multiprotein Complex Containing HDAC3 and SMRT/N-CoR

Fischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W., & Verdin, E. (2002) · Molecular Cell · doi:10.1016/s1097-2765(01)00429-4 · Cited by 754 · see citing works

Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family

Gao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744 · see citing works

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Piekarz, R., Frye, R., Turner, M. L. C., Wright, J. J., Allen, S. L., Kirschbaum, M. H., Zain, J. M., Prince, H. M., Leonard, J. P., Geskin, L. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6150 · Cited by 739 · see citing works

Chemical phylogenetics of histone deacetylases

Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720 · see citing works

Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases

Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710 · cited 1× · see citing works

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

Whittaker, S. J., Demierre, M., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M. A., Scarisbrick, J. J., Reddy, S. A., Robak, T., Becker, J. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9066 · Cited by 666 · see citing works

Acetylation of non-histone proteins modulates cellular signalling at multiple levels

Spange, S., Wagner, T., Heinzel, T., & Krämer, O. H. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.027 · Cited by 665 · see citing works

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1759 · Cited by 659 · see citing works

Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells

Leder, A., & Leder, P. (1975) · Cell · doi:10.1016/0092-8674(75)90107-5 · Cited by 659 · see citing works

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor

Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404603101 · Cited by 638 · see citing works

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387365 · Cited by 616 · see citing works

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

Nebbioso, A., Clarke, N. M., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Álvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2004) · Nature Medicine · doi:10.1038/nm1161 · Cited by 611 · see citing works

The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3

Guenther, M. G., Barak, O., & Lazar, M. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.18.6091-6101.2001 · Cited by 611 · see citing works

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

Hideshima, T., Bradner, J. E., Wong, J. Y. Y., Chauhan, D., Richardson, P. G. G., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 598 · see citing works

HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle

Deardorff, M. A., Bando, M., Nakato, R., Watrin, E., Itoh, T., Minamino, M., Saitoh, K., Komata, M., Katou, Y., Clark, D., et al. (2012) · Nature · doi:10.1038/nature11316 · Cited by 577 · see citing works

Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer

Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575 · see citing works

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., & Pelicci, P. G. (2004) · Nature Medicine · doi:10.1038/nm1160 · Cited by 515 · see citing works

Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO

Gelmetti, V., Zhang, J., Fanelli, M., Minucci, S., Pelicci, P. G., & Lazar, M. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.7185 · Cited by 489 · see citing works

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

Weichert, W., Roske, A.-E., Gekeler, V., Beckers, T. L., Stephan, C., Jung, K., Fritzsche, F., Niesporek, S., Denkert, C., Dietel, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604199 · Cited by 478 · see citing works

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458 · see citing works

Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

Ryan, Q. C., Headlee, D. J., Acharya, M. R., Sparreboom, A., Trepel, J. B., Ye, Z., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.188 · Cited by 412 · see citing works

Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed

Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404 · see citing works

Histone deacetylase 8 in neuroblastoma tumorigenesis

Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398 · see citing works

Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages

Chen, X., Barozzi, I., Termanini, A., Prosperini, E., Recchiuti, A., Dalli, J., Mietton, F., Matteoli, G., Hiebert, S., & Natoli, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121131109 · Cited by 397 · see citing works

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group

Lobera, M., Madauss, K. P., Pohlhaus, D. T., Wright, Q. G., Trocha, M., Schmidt, D. R., Baloglu, E., Trump, R. P., Head, M. S., Hofmann, G. A., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1223 · Cited by 384 · see citing works

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

Weichert, W., Roske, A.-E., Niesporek, S., Noske, A., Buckendahl, A., Dietel, M., Gekeler, V., Boehm, M., Beckers, T. L., & Denkert, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0990 · Cited by 362 · see citing works

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis

Weichert, W., Roske, A.-E., Gekeler, V., Beckers, T. L., Ebert, M. P., Pross, M., Dietel, M., Denkert, C., & Röcken, C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70004-4 · Cited by 361 · see citing works

Hdac3 is essential for the maintenance of chromatin structure and genome stability

Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., Yenamandra, A., Locke, K., Yuan, J.-L., Bonine-Summers, A. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.022 · Cited by 353 · see citing works

Increased expression of histone deacetylase 2 is found in human gastric cancer

SONG, J., Noh, J. H., LEE, J. H., Eun, J. W., Ahn, Y. M., Kim, S. Y., Lee, S. H., Park, W. S., Yoo, N. J., Lee, J. Y., et al. (2005) · Apmis · doi:10.1111/j.1600-0463.2005.apm_04.x · Cited by 347 · see citing works

SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor α (RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukemia

Hong, S.-H., David, G., Wong, C.-W., Dejean, A., & Privalsky, M. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9028 · Cited by 341 · see citing works

Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein

Dhordain, P., Albagli, O., Lin, R. J., Ansieau, S., Quief, S., Leutz, A., Kerckaert, J., Evans, R. M., & Leprince, D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10762 · Cited by 336 · see citing works

Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-binding Domain

Bottomley, M. J., Surdo, P. L., Giovine, P. D., Cirillo, A., Scarpelli, R., Ferrigno, F., JONES, P. G., Neddermann, P., Francesco, R. D., Steinkühler, C., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803514200 · Cited by 319 · see citing works

HDAC inhibitor‐based therapies: Can we interpret the code?

New, M. I., Olzscha, H., & Thangue, N. B. L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 310 · see citing works

Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*

Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., Hamaguchi, M., Hara, Y., Kobayashi, S., & Iwase, H. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-6001-1 · Cited by 307 · see citing works

HDAC6 Expression Is Correlated with Better Survival in Breast Cancer

Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Omoto, Y., Ando, Y., Mita, K., Hamaguchi, M., Hayashi, S., & Iwase, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0455 · Cited by 295 · see citing works

Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progressionPreprint

Yamaguchi, T., Cubizolles, F., Zhang, Y., Reichert, N., Kohler, H., Seiser, C., & Matthias, P. (2010) · Genes & Development · doi:10.1101/gad.552310 · Cited by 294 · see citing works

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

Ropero, S., Fraga, M. F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., Caballero, R., Alaminos, M., Setién, F., Paz, M. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1773 · Cited by 290 · see citing works

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z., Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B., & Grant, S. (1999) · Oncogene · doi:10.1038/sj.onc.1203176 · Cited by 285 · see citing works

A phosphorylation-acetylation switch regulates STAT1 signalingPreprint

Krämer, O. H., Knauer, S. K., Greiner, G., Jandt, E., Reichardt, S., Gührs, K., Stauber, R. H., Böhmer, F., & Heinzel, T. (2009) · Genes & Development · doi:10.1101/gad.479209 · Cited by 282 · see citing works

Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein

David, G., Alland, L., Hong, S.-H., Wong, C.-W., DePinho, R. A., & Dejean, A. (1998) · Oncogene · doi:10.1038/sj.onc.1202043 · Cited by 281 · see citing works

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

Hideshima, T., Richardson, P. G. G., & Anderson, K. C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0433 · Cited by 266 · see citing works

Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

Younes, A., Sureda, A. M., Ben‐Yehuda, D., Zinzani, P. L., Ong, T.-C., Prince, H. M., Harrison, S. J., Kirschbaum, M. H., Johnston, P. B., Gallagher, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1350 · Cited by 263 · see citing works

Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase Activity

Schuetz, A., Min, J., Allali‐Hassani, A., Schapira, M., Shuen, M., Loppnau, P., Mazitschek, R., Kwiatkowski, N. P., Lewis, T. A., Maglathin, R. L., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707362200 · Cited by 261 · see citing works

Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides

Bressi, J. C., Jennings, A. J., Skene, R., Wu, Y., Melkus, R., Jong, R. D., O’Connell, S., Grimshaw, C. E., Navre, M., & Gangloff, A. R. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.091 · Cited by 261 · cited 16× · see citing works

Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer

Saji, S., Kawakami, M., Hayashi, S., Yoshida, N., Hirose, M., Horiguchi, S.-I., Ito, A., Funata, N., Schreiber, S. L., Yoshida, M., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208646 · Cited by 259 · see citing works

Differential expression of selected histone modifier genes in human solid cancers

Özdağ, H., Teschendorff, A. E., Ahmed, A. A., Hyland, S. J., Blenkiron, C., Bobrow, L., Veerakumarasivam, A., Burtt, G. J., Subkhankulova, T., Arends, M. J., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-90 · Cited by 258 · see citing works

Role for Histone Deacetylase 1 in Human Tumor Cell Proliferation

Senese, S., Zaragoza, K., Minardi, S. P., Muradore, I., Ronzoni, S., Passafaro, A., Bernard, L., Draetta, G. F., Alcalay, M., Seiser, C., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00494-07 · Cited by 256 · see citing works

A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

Rambaldi, A., Dellacasa, C. M., Finazzi, G., Carobbio, A., Ferrari, M. L., Guglielmelli, P., Gattoni, E., Salmoiraghi, S., Finazzi, M. C., Tollo, S. D., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08266.x · Cited by 244 · see citing works

Histone Deacetylase Inhibitors Down-Regulate bcl-2 Expression and Induce Apoptosis in t(14;18) Lymphomas

Duan, H., Heckman, C. A., & Boxer, L. M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1608-1619.2005 · Cited by 240 · see citing works

Trials with ‘epigenetic’ drugs: An update

Nebbioso, A., Carafa, V., Benedetti, R., & Altucci, L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.004 · Cited by 237 · see citing works

Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis

Krusche, C. A., W�lfing, P., Kersting, C., Vloet, A. J., B�cker, W., Kiesel, L., Beier, H. M., & Alfer, J. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1668-2 · Cited by 230 · see citing works

Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis

Wilting, R. H., Yanover, E., Heideman, M. R., Jacobs, H., Horner, J. W., van der Torre, J., DePinho, R. A., & Dannenberg, J. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.136 · Cited by 230 · see citing works

Safety and efficacy of an oral histone deacetylase inhibitor in systemic‐onset juvenile idiopathic arthritis

Vojinović, J., DAMJANOV, N. S., D’Urzo, C., Furlan, A., Sušić, G., Pasic, S., Iagăru, N., Stefan, M., & Dinarello, C. A. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30238 · Cited by 226 · see citing works

HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21

Wilson, A. J., Byun, D.-S., Nasser, S., Murray, L. B., Ayyanar, K., Arango, D., Figueroa, M. E., Melnick, A. M., Kao, G. D., Augenlicht, L. H., et al. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-02-0139 · Cited by 214 · see citing works

Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients

Osada, H., Tatematsu, Y., Saito, H., Yatabe, Y., Mitsudomi, T., & Takahashi, T. (2004) · International Journal of Cancer · doi:10.1002/ijc.20395 · Cited by 213 · see citing works

research paper: Differential expression of <i>HDAC3, HDAC7</i> and <i>HDAC9</i> is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

Moreno, D. A., Scrideli, C. A., Cortez, M. A. A., De Paula Queiroz, R., Valera, E. T., Da Silva Silveira, V., Yunes, J. A., Brandalise, S. R., & Tone, L. G. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08301.x · Cited by 208 · see citing works

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

Lindemann, R. K., Newbold, A., Whitecross, K. F., Cluse, L. A., Frew, A. J., Ellis, L., Williams, S. P., Wiegmans, A. P., Dear, A. E., Scott, C. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702294104 · Cited by 199 · see citing works

HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses

Bolden, J. E., Shi, W., Jankowski, K., Kan, C.-Y., Cluse, L. A., Martin, B. P., MacKenzie, K. L., Smyth, G. K., & Johnstone, R. W. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.9 · Cited by 197 · see citing works

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

Younes, A., Oki, Y., Bociek, R. G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70265-0 · Cited by 196 · see citing works

HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth

Milde, T., Oehme, I., Korshunov, A., Kopp‐Schneider, A., Remke, M., Northcott, P. A., Deubzer, H. E., Lodrini, M., Taylor, M. D., von Deimling, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0395 · Cited by 192 · see citing works

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

Giaccone, G., Rajan, A., Berman, A. W., Kelly, R. J., Szabo, E. M., López-Chávez, A., Trepel, J. B., Lee, M.-J., Cao, L., Espinoza‐Delgado, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4467 · Cited by 191 · see citing works

Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

Fantin, V. R., Loboda, A. P., Paweletz, C. P., Hendrickson, R. C., Pierce, J. W., Roth, J. A., Li, L., Gooden, F., Korenchuk, S., Hou, X., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6091 · Cited by 176 · see citing works

Clinical Significance of Histone Deacetylase 1 Expression in Patients with Hepatocellular Carcinoma

Rikimaru, T., Taketomi, A., Yamashita, Y., Shirabe, K., Hamatsu, T., Shimada, M., & Maehara, Y. (2007) · Oncology · doi:10.1159/000111106 · Cited by 172 · see citing works

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., & Eckhardt, S. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1461 · Cited by 171 · see citing works

Erratum: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

Insinga, A., Monestiroli, S., Ronzoni, S., et al. (2005) · Nature Medicine · doi:10.1038/nm0205-233a · Cited by 168 · see citing works

HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism

Mottet, D., Pirotte, S., Lamour, V., Hagedorn, M., Javerzat, S., Bikfalvi, A., Bellahcène, A., Verdin, E. M., & CASTRONOVO, V. (2008) · Oncogene · doi:10.1038/onc.2008.371 · Cited by 156 · see citing works

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

Khan, O. A., Fotheringham, S. A., Wood, V. H. J., Stimson, L., Zhang, C., Pezzella, F., Duvic, M. A., Kerr, D. J., & Thangue, N. B. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913912107 · Cited by 153 · see citing works

Histone Deacetylase 2 Modulates p53 Transcriptional Activities through Regulation of p53-DNA Binding Activity

Harms, K. L., & Chen, X. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4397 · Cited by 152 · see citing works

Effects of Treatment with Histone Deacetylase Inhibitors in Solid Tumors: A Review Based on 30 Clinical Trials

Qiu, T., Zhou, L. Q., Zhu, W., Wang, T., Wang, J., Shu, Y., & Liu, P. (2013) · Future Oncology · doi:10.2217/fon.12.173 · Cited by 148 · see citing works

Modulation of Renal Disease in MRL/lpr Mice by Suberoylanilide Hydroxamic Acid

Reilly, C. M., Mishra, N., Miller, J. M., Joshi, D., Ruiz, P., Richon, V. M., Marks, P. A., & Gilkeson, G. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.4171 · Cited by 146 · see citing works

Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung

Minamiya, Y., Ono, T., Saito, H., Takahashi, N., Ito, M., Mitsui, M., Motoyama, S., & Ogawa, J. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.019 · Cited by 138 · see citing works

Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis

Fotheringham, S., Epping, M. T., Stimson, L., Khan, O., Wood, V., Pezzella, F., Bernards, R., & La Thangue, N. B. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.001 · Cited by 138 · see citing works

HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins

Jung, K. H., Noh, J. H., Kim, J. K., Eun, J. W., Bae, H. J., Xie, H. J., Chang, Y. G., Kim, M., Park, H., Lee, J. Y., et al. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24090 · Cited by 130 · see citing works

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

Duvic, M., Dummer, R., Becker, J. C., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.017 · Cited by 127 · see citing works

Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas

Taylor, B. S., DeCarolis, P. L., Angeles, C. V., Brenet, F. A., Schultz, N. D., Antonescu, C. R., Scandura, J. M., Sander, C., Viale, A. J., Socci, N. D., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0181 · Cited by 124 · see citing works

Histone deacetylase inhibitors and genomic instability

Éot-Houllier, G., Fulcrand, G., Magnaghi-Jaulin, L., & Jaulin, C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.005 · Cited by 121 · see citing works

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

Dong, M., Ning, Z., Xing, P.-Y., Xu, J.-L., Cao, H., Dou, G.-F., Meng, Z., Shi, Y., Lu, X., & Feng, F.-Y. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1847-5 · Cited by 120 · see citing works

A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance

Santoro, F., Botrugno, O. A., Zuffo, R. D., Pallavicini, I., Matthews, G. M., Cluse, L. A., Barozzi, I., Senese, S., Fornasari, L., Moretti, S., et al. (2013) · Blood · doi:10.1182/blood-2012-10-461988 · Cited by 120 · see citing works

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model

Sandi, C., Pinto, R. M., Al‐Mahdawi, S., Ezzatizadeh, V., Barnes, G., Jones, S. E., Rusche, J. R., Gottesfeld, J. M., & Pook, M. A. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.02.016 · Cited by 115 · see citing works

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

Ellis, L., Bots, M. L., Lindemann, R. K., Bolden, J. E., Newbold, A., Cluse, L. A., Scott, C. L., Strasser, A., Atadja, P. W., Lowe, S. W., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182758 · Cited by 114 · see citing works

HDAC11 is a novel drug target in carcinomas

Deubzer, H. E., Schier, M. C., Oehme, I., Lodrini, M., Haendler, B., Sommer, A., & Witt, O. (2013) · International Journal of Cancer · doi:10.1002/ijc.27876 · Cited by 112 · see citing works

Genetic dissection of histone deacetylase requirement in tumor cells

Haberland, M., Johnson, A., Mokalled, M. H., Montgomery, R. L., & Olson, E. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903139106 · Cited by 110 · see citing works

Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis

Zhang, Y., Adachi, M., Kawamura, R., & Imai, K. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401686 · Cited by 110 · see citing works

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T‐cell lymphoma

Marquard, L., Gjerdrum, L. M. R., Christensen, I. J., Jensen, P. B., Sehested, M., & Ralfkiaer, E. M. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03109.x · Cited by 107 · see citing works

Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

Bonfils, C., Kalita, A., Dubay, M., Siu, L. L., Carducci, M. A., Reid, G. K., Martell, R. E., Besterman, J. M., & Li, Z. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4427 · Cited by 103 · see citing works

Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors

Park, J., Kim, S.-H., Choi, M.-C., Lee, J., Oh, D., Im, S., Bang, Y., & Kim, T.-Y. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.056 · Cited by 97 · see citing works

Mechanisms of Transcriptional Repression by Myc

Kleine‐Kohlbrecher, D., Adhikary, S., & Eilers, M. (2006) · Springer eBooks · doi:10.1007/3-540-32952-8_3 · Cited by 96 · see citing works

Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function

Heideman, M. R., Wilting, R. H., Yanover, E., Velds, A., de Jong, J., Kerkhoven, R. M., Jacobs, H., Wessels, L. F. A., & Dannenberg, J. (2013) · Blood · doi:10.1182/blood-2012-08-450916 · Cited by 91 · see citing works

Histone Deacetylases 9 and 10 Are Required for Homologous Recombination

Kotian, S., Liyanarachchi, S., Zelent, A., & Parvin, J. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.194233 · Cited by 88 · see citing works

Expansion of the Lysine Acylation Landscape

Olsen, C. A. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201200316 · Cited by 83 · see citing works

HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy

Lin, K., Wang, Y., Chen, C., Ho, C., Su, W.-H., & Jou, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0633 · Cited by 81 · see citing works

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma

Hauschild, A., Trefzer, U., Garbe, C., Kaehler, K. C., Ugurel, S., Kiecker, F., Eigentler, T., Krissel, H., Schott, A., & Schadendorf, D. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e328307c248 · Cited by 79 · see citing works

Histone Deacetylase 7 and FoxA1 in Estrogen-Mediated Repression of RPRM

Malik, S., Jiang, S., Garee, J. P., Verdin, E. M., Lee, A. V., O’Malley, B. W., Zhang, M., Belaguli, N. S., & Oesterreich, S. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00907-09 · Cited by 79 · see citing works

Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma

Adams, H., Fritzsche, F. R., Dirnhofer, S., Kristiansen, G., & Tzankov, A. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003796609 · Cited by 78 · see citing works

A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

Banerji, U., van Doorn, L., Papadatos-Pastos, D., Kristeleit, R. S., Debnam, P. M., Tall, M., Stewart, A., Raynaud, F. I., Garrett, M. D., Toal, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3165 · Cited by 77 · see citing works

Drug Targeting to Monocytes and Macrophages Using Esterase-Sensitive Chemical Motifs

Needham, L. A., Davidson, A. H., Bawden, L. J., Belfield, A. J., Bone, E. A., Brotherton, D. H., Bryant, S., Charlton, M. H., Clark, V. L., Davies, S. J., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183640 · Cited by 70 · see citing works

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

Newbold, A., Lindemann, R. K., Cluse, L. A., Whitecross, K. F., Dear, A. E., & Johnstone, R. W. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2256 · Cited by 67 · see citing works

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

Razak, A. R. A., Hotte, S. J., Siu, L. L., Chen, E. X., Hirte, H. W., Powers, J., Walsh, W. R., Stayner, L.-A., Laughlin, A., Novotny‐Diermayr, V., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.13 · Cited by 66 · see citing works

HDAC4 Represses Vascular Endothelial Growth Factor Expression in Chondrosarcoma by Modulating RUNX2 Activity

Sun, X., Lei, W., Chen, Q., & Terek, R. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.019091 · Cited by 65 · see citing works

Targeting class I histone deacetylases in cancer therapy

Delcuve, G. P., Khan, D. H., & Davie, J. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.729042 · Cited by 65 · see citing works

Destabilization of ERBB2 Transcripts by Targeting 3′ Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6

Scott, G. K., Marx, C., Berger, C. E., Saunders, L. R., Verdin, E. M., Schäfer, S., Jung, M., & Benz, C. C. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2110 · Cited by 58 · see citing works

Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARα as a component of the N-CoR co-repressor complex to repress transcription in vivo

Atsumi, A., Tomita, A., Kiyoi, H., & Naoe, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.047 · Cited by 51 · see citing works

Discovery of adamantane based highly potent HDAC inhibitors

Gopalan, B., Ponpandian, T., Kachhadia, V. V., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.002 · Cited by 44 · see citing works

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors

New, M., Olzscha, H., Liu, G., Khan, O., Stimson, L., McGouran, J. F., Kerr, D. J., Coutts, A. S., Kessler, B. M., Middleton, M. R., et al. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.47 · Cited by 42 · see citing works

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

Yong, W. P., Goh, B. C., Soo, R. A., Toh, H. C., Ethirajulu, K., Wood, J. M., Novotny‐Diermayr, V., Lee, S. C., Yeo, W. L., Chan, D., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq784 · Cited by 37 · see citing works

Rationale for the Development of 2-Aminobenzamide Histone Deacetylase Inhibitors as Therapeutics for Friedreich Ataxia

Soragni, E., Xu, C., Plasterer, H. L., Jacques, V., Rusche, J. R., & Gottesfeld, J. M. (2012) · Journal of Child Neurology · doi:10.1177/0883073812448533 · Cited by 36 · see citing works

Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins

Hiebert, S. W., Lutterbach, B. A., Durst, K. L., Wang, L., Linggi, B. E., Wu, S. W., Wood, L. D., Amann, J. M., King, D., & Hou, Y. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100302 · Cited by 30 · see citing works

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

Raje, N. S., Hari, P., Vogl, D. T., Jagannath, S., Orlowski, R. Z., Supko, J. G., Stephenson, P. A., Jones, S. S., Wheeler, C., & Lonial, S. (2012) · Blood · doi:10.1182/blood.v120.21.4061.4061 · Cited by 26 · see citing works

A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Evens, A. M., Vose, J. M., Harb, W. A., et al. (2012) · Blood · doi:10.1182/blood.v120.21.55.55 · Cited by 25 · see citing works

Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.

Hofmeister, C. C., Liu, Z., Bowers, M. A., et al. (2012) · Blood · doi:10.1182/blood.v120.21.2955.2955 · Cited by 7 · see citing works

Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma

Child, F. J., Ortiz-Romero, P. L., Alvarez, R., et al. (2012) · Blood · doi:10.1182/blood.v120.21.3676.3676 · Cited by 5 · see citing works

Discovering the Binding Modes of Natural Products with Histone Deacetylase 1

Zhang, L., Li, M., Zhang, L., et al. (2012) · Medicinal Chemistry · doi:10.2174/157340613804488314 · Cited by 3 · see citing works

Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Ghobrial, I. M., Banwait, R., Poon, T. W., et al. (2011) · Blood · doi:10.1182/blood.v118.21.2706.2706 · Cited by 2 · see citing works

Combination therapy in combating cancer

Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543 · see citing works

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · see citing works

Histone Deacetylase Inhibitors as Anticancer Drugs

Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206 · see citing works

Histone deacetylase 6 structure and molecular basis of catalysis and inhibition

Hai, Y., & Christianson, D. W. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2134 · Cited by 521 · see citing works

Chromatin repressive complexes in stem cells, development, and cancer

Laugesen, A., & Helin, K. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.05.006 · Cited by 352 · see citing works

Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid

Yuille, S., Reichardt, N., Panda, S., Dunbar, H., & Mulder, I. E. (2018) · PLOS ONE · doi:10.1371/journal.pone.0201073 · Cited by 257 · see citing works

Insights into the activation mechanism of class I HDAC complexes by inositol phosphates

Watson, P. J., Millard, C. J., Riley, A. M., Robertson, N. S., Wright, L. C., Godage, H. Y., Cowley, S. M., Jamieson, A. G., Potter, B. V. L., & Schwabe, J. W. R. (2016) · Nature Communications · doi:10.1038/ncomms11262 · Cited by 244 · see citing works

Integrative regulation of physiology by histone deacetylase 3

Emmett, M. J., & Lazar, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0076-0 · Cited by 202 · see citing works

Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology

Shah, R. R. (2019) · Drug Safety · doi:10.1007/s40264-018-0773-9 · Cited by 197 · see citing works

A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC

Samaraweera, L., Adomako, A., Rodriguez-Gabin, A., & McDaid, H. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-01964-1 · Cited by 183 · see citing works

Targeting Class I Histone Deacetylases in a “Complex” Environment

Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180 · see citing works

A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma

Yang, W., Feng, Y., Zhou, J., Cheung, O. K.-W., Cao, J., Wang, J., Tang, W., Tu, Y., Xu, L., Wu, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6804 · Cited by 172 · see citing works

Epigenetic modifications: Key players in cancer heterogeneity and drug resistance

Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A.-S., & Bhat, A. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101821 · Cited by 151 · see citing works

Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases

Porter, N. J., & Christianson, D. W. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.01.004 · Cited by 146 · see citing works

Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants

Marek, M., Shaik, T. B., Heimburg, T., Chakrabarti, A., Lancelot, J., Ramos-Morales, E., Da Veiga, C., Kalinin, D., Melesina, J., Robaa, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01087 · Cited by 123 · see citing works

Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review

Sarkar, R., Banerjee, S., Amin, S. A., Adhikari, N., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112171 · Cited by 121 · see citing works

HDAC8 catalyzes the hydrolysis of long chain fatty acyl lysine

Aramsangtienchai, P., Spiegelman, N. A., He, B., Miller, S. P., Dai, L., Zhao, Y., & Lin, H. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00396 · Cited by 118 · see citing works

HDAC3 inhibition upregulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy

Deng, S., Hu, Q., Zhang, H., Yang, F., Peng, C., & Huang, C. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1068 · Cited by 116 · see citing works

Targeting the acetylation signaling pathway in cancer therapy

Dang, F., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.001 · Cited by 109 · see citing works

MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF-, NRAS</i> -, and <i>NF1</i> -Mutant Melanomas

Maertens, O., Kuzmickas, R., Manchester, H. E., Emerson, C. E., Gavin, A. G., Guild, C. J., Wong, T. C., De Raedt, T., Bowman-Colin, C., Hatchi, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0879 · Cited by 95 · see citing works

Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance

Krumm, A., Barckhausen, C., Kücük, P., Tomaszowski, K.-H., Loquai, C., Fahrer, J., Krämer, O. H., Kaina, B., & Roos, W. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2680 · Cited by 91 · see citing works

Cell signaling and cancer: a mechanistic insight into drug resistance

Panda, M., & Biswal, B. K. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04958-6 · Cited by 89 · see citing works

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications

Harada, T., Ohguchi, H., Grondin, Y., Kikuchi, S., Sagawa, M., Tai, Y.-T., Mazitschek, R., Hideshima, T., & Anderson, K. C. (2017) · Leukemia · doi:10.1038/leu.2017.144 · Cited by 89 · see citing works

Entinostat induces antitumor immune responses through immune editing of tumor neoantigens

Truong, A. S., Zhou, M., Krishnan, B., Utsumi, T., Manocha, U., Stewart, K. G., Beck, W., Rose, T. L., Milowsky, M. I., He, X., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138560 · Cited by 84 · see citing works

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia

Long, J., Jia, M.-Y., Fang, W.-Y., Chen, X.-J., Mu, L.-L., Wang, Z.-Y., Shen, Y., Xiang, R.-F., Wang, L.-N., Wang, L., et al. (2020) · Blood · doi:10.1182/blood.2019003538 · Cited by 84 · see citing works

Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells

Was, H., Krol, S. K., Rotili, D., Mai, A., Wojtas, B., Kaminska, B., & Maleszewska, M. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0598-5 · Cited by 78 · see citing works

Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response

Long, J., Fang, W. Y., Chang, L., Gao, W. H., Shen, Y., Jia, M. Y., Zhang, Y. X., Wang, Y., Dou, H. B., Zhang, W. J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.130 · Cited by 78 · see citing works

Innovative Strategies for Selective Inhibition of Histone Deacetylases

Maolanon, A. R., Madsen, A. S., & Olsen, C. A. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.06.011 · Cited by 72 · see citing works

Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors

López-Cobo, S., Pieper, N., Campos-Silva, C., García-Cuesta, E. M., Reyburn, H. T., Paschen, A., & Valés-Gómez, M. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1392426 · Cited by 71 · see citing works

CRISPR screen identifies the NCOR/HDAC3 complex as a major suppressor of differentiation in rhabdomyosarcoma

Phelps, M. P., Bailey, J. N., Vleeshouwer-Neumann, T., & Chen, E. Y. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610270114 · Cited by 62 · see citing works

Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine

Staberg, M., Michaelsen, S. R., Rasmussen, R. D., Villingshøj, M., Poulsen, H. S., & Hamerlik, P. (2017) · Cellular Oncology · doi:10.1007/s13402-016-0301-9 · Cited by 62 · see citing works

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)

Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62 · see citing works

Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring <i>RAS</i> Mutations

Yamada, T., Amann, J. M., Tanimoto, A., Taniguchi, H., Shukuya, T., Timmers, C., Yano, S., Shilo, K., & Carbone, D. P. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0146 · Cited by 44 · see citing works

Antifungal Activity of Compounds Targeting the Hsp90‐Calcineurin Pathway Against Various Mould Species

Lamoth, F., Alexander, B. D., Juvvadi, P. R., & Steinbach, W. J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku549 · Cited by 47 · see citing works

Chemical editing of macrocyclic natural products and kinetic profiling reveal slow, tight-binding histone deacetylase inhibitors with picomolar affinities

Kitir, B., Maolanon, A. R., Ohm, R. G., Colaço, A. R., Fristrup, P., Madsen, A. S., & Olsen, C. A. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00725 · Cited by 38 · see citing works

The discovery of novel HDAC3 inhibitors via virtual screening and <i>in vitro</i> bioassay

Xia, J., Hu, H., Xue, W., Wang, X. S., & Wu, S. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1437156 · Cited by 24 · see citing works

Progress in clinical trial of histone deacetylase (HDAC) inhibitors for non-small cell lung cancers*

Hu, X., Wang, L., Lin, L., et al. (2014)

Potential non-oncological applications of histone deacetylase inhibitors.

Ververis, K., & Karagiannis, T. C. (2011) · Europe PMC (PubMed Central) · Cited by 29 · see citing works

The Emerging Role of Histone Deacetylase Inhibitors in Treating T-cell Lymphomas

Horwitz, S. M. (2010) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-010-0067-5 · Cited by 12 · see citing works

Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches

Marsh, A. M., Narramore, R., Chapple, K. S., Lobo, A., Wild, J. R. L., & Corfe, B. M. (2013) · Clinical Investigation · doi:10.4155/cli.13.36 · Cited by 3 · see citing works

An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis.

Ververis, K., & Karagiannis, T. C. (2012) · PubMed Central · Cited by 23 · see citing works